Summary
The value screen selects 50 U.S. non-financial small-cap stocks with a market capitalisation of at least $50 million, ranked by price-to-book ratio using point-in-time SEC filings. Each stock starts at an equal 2% weight at the March and September rebalances.
From March 2006 to September 2026, the backtest returned 20.6% a year with 30.9% annualised volatility. Its Sharpe ratio was 0.71, compared with 0.55 for the Fama–French Market Portfolio (11.2% CAGR, 19.6% volatility).
The Fama–French five-factor model explained 81% of daily return variation (R² = 0.81) and left +11.5% annualised alpha (p < 0.001). Use the interactive chart above to switch between the full 20-year sample, the 2006–2015 GFC regime, and the 2016–2026 modern cycle, or toggle to underwater drawdowns.
1. Performance Through Stress: 2006–2015 (GFC & Recovery)
Cheap, cyclical small-cap stocks took heavy losses as credit froze during 2008. Select 2006–2015 in the interactive chart above to inspect the peak-to-trough path and rebound.
- Drawdown: From July 2007 to November 2008, the portfolio fell 67.4% from peak to trough, compared with 54.6% for the Fama–French Market benchmark.
- Recovery: The portfolio regained its prior peak in 8.4 months from the trough, compared with 35.7 months for the market benchmark.
- Factors: Market (
+1.06), size (+0.92), value (+0.46) and profitability (+0.14) loadings were all statistically significant (R² = 0.88), with +10.1% annualised alpha (p = 0.002). - Returns: The portfolio returned 16.6% a year with 29.8% annualised volatility (Sharpe
0.63vs.0.38market). It finished negative in 6 of 20 half-year periods.
2. Modern Market Regime: 2016–2026 (COVID-19 & Rate Cycles)
The 2016–2019 expansion ended abruptly in March 2020, followed by fiscal stimulus, rising interest rates in 2022–2023, and a mega-cap-led equity rally.
- Drawdown: The portfolio fell 54.2% from January to March 2020, versus 34.2% for the market benchmark.
- Recovery: NAV recovered its pre-crash high in 2.6 months, versus 4.4 months for the benchmark.
- Factors: Market (
+1.09), size (+1.11) and value (+0.65) remained the dominant exposures (R² = 0.76), alongside +11.9% annualised alpha (p = 0.013). - Returns: The portfolio returned 24.5% a year with 31.8% annualised volatility (Sharpe
0.78vs.0.74market), posting losses in 5 of 22 half-year periods.
Full-Sample & Regime Summary
| Metric | Full Sample (2006–2026) | 2006–2015 Regime | 2016–2026 Regime |
|---|---|---|---|
| Annualised Return | 20.6% (11.2% Mkt) | 16.6% (7.2% Mkt) | 24.5% (15.2% Mkt) |
| Annualised Volatility | 30.9% (19.6% Mkt) | 29.8% (21.0% Mkt) | 31.8% (18.3% Mkt) |
| Sharpe Ratio | 0.71 (0.55 Mkt) | 0.63 (0.38 Mkt) | 0.78 (0.74 Mkt) |
| Max Drawdown | -67.4% (-54.6% Mkt) | -67.4% (-54.6% Mkt) | -54.2% (-34.2% Mkt) |
| Post-Trough Recovery | 8.4 months (35.7m Mkt) | 8.4 months | 2.6 months (4.4m Mkt) |
| Negative Half-Year Periods | 11 / 42 | 6 / 20 | 5 / 22 |
| Fama–French 5-Factor R² | 0.81 | 0.88 | 0.76 |
| FF5 Annualised Alpha | +11.5% (p < 0.001) | +10.1% (p = 0.002) | +11.9% (p = 0.013) |
Conclusion
Small-cap value delivered the strongest long-term compounding and highest risk-adjusted return across all four Systematic 50s portfolios, but required enduring 54%–67% drawdowns during liquidity shocks. Comparing these results with US Mid-Cap Value 50 highlights how strongly the value premium concentrates in capacity-constrained smaller stocks.